From: A review on gut microbiota: a central factor in the pathophysiology of obesity
Paper | No. patient | Demographic | Type of study | Mode of delivery | Country of Study | Frozen / fresh | Outcomes | Significant Adverse Events |
---|---|---|---|---|---|---|---|---|
Allegretti et al. [129] | 22 11 = allogenic lean FMT 11 = placebo | Obese BMI > 35 without metabolic complications | DBRCT* 1:1 | Capsules | USA | Unrelated donor Frozen stool | No change in GLP1 in either group No significant changes in obesity biomarkers No changes in BMI Sustained shift of microbiome towards donor profile | Nil |
Vrieze et al. [47] | 18 9 = Lean allogenic 9 = autologous FMT | Treatment naïve males with metabolic syndrome | RCT* placebo controlled pilot study 1:1 | Nasoduodenal tube | Netherlands | Unrelated donor Fresh stool | Improvement in peripheral insulin sensitivity at 6 weeks in allogenic FMT Gut bacterial diversity significantly increased post allogenic FMT | Nil |
Smits et al. [130] | 20 10 = allogenic lean vegan FMT 10 = autologous FMT | Male cohort with metabolic syndrome | DBRCT pilot study 1:1 | Nasoduodenal tube | Netherlands | Unrelated donor Fresh stool | No changes in faecal diversity 2 weeks post FMT Allogenic FMT shifted microbiome profile towards vegan No changes in vascular inflammation | Nil |